MX2013004123A - Composiciones antitusigenas que comprenden memantina. - Google Patents

Composiciones antitusigenas que comprenden memantina.

Info

Publication number
MX2013004123A
MX2013004123A MX2013004123A MX2013004123A MX2013004123A MX 2013004123 A MX2013004123 A MX 2013004123A MX 2013004123 A MX2013004123 A MX 2013004123A MX 2013004123 A MX2013004123 A MX 2013004123A MX 2013004123 A MX2013004123 A MX 2013004123A
Authority
MX
Mexico
Prior art keywords
memantine
compositions
antitussive compositions
enhancer
antitussive
Prior art date
Application number
MX2013004123A
Other languages
English (en)
Inventor
Blake Paterson
Mark Ginski
Brendan Canning
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of MX2013004123A publication Critical patent/MX2013004123A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente se describen composiciones de memantina y sus métodos de uso. En algunas realizaciones, las composiciones comprenden memantina y un potenciador de la absorción o memantina y un potenciador de la eliminación o memantina y un potenciador de la absorción y un potenciador de la eliminación.
MX2013004123A 2010-10-12 2011-10-12 Composiciones antitusigenas que comprenden memantina. MX2013004123A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US39225010P 2010-10-12 2010-10-12
US39229110P 2010-10-12 2010-10-12
US41266410P 2010-11-11 2010-11-11
US41266010P 2010-11-11 2010-11-11
US201161452710P 2011-03-15 2011-03-15
PCT/US2011/056004 WO2012051333A1 (en) 2010-10-12 2011-10-12 Antitussive compositions comprising memantine

Publications (1)

Publication Number Publication Date
MX2013004123A true MX2013004123A (es) 2013-12-16

Family

ID=45938703

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004123A MX2013004123A (es) 2010-10-12 2011-10-12 Composiciones antitusigenas que comprenden memantina.

Country Status (12)

Country Link
US (2) US8501816B2 (es)
EP (1) EP2627323A4 (es)
JP (1) JP2013539790A (es)
CN (1) CN103347506A (es)
AU (1) AU2011316565A1 (es)
BR (1) BR112013008985A2 (es)
CA (1) CA2814194A1 (es)
IL (1) IL225716A0 (es)
MX (1) MX2013004123A (es)
RU (1) RU2013121270A (es)
SG (1) SG189395A1 (es)
WO (1) WO2012051333A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9293060B2 (en) 2010-05-06 2016-03-22 Ai Cure Technologies Llc Apparatus and method for recognition of patient activities when obtaining protocol adherence data
US9883786B2 (en) 2010-05-06 2018-02-06 Aic Innovations Group, Inc. Method and apparatus for recognition of inhaler actuation
US10116903B2 (en) 2010-05-06 2018-10-30 Aic Innovations Group, Inc. Apparatus and method for recognition of suspicious activities
US9875666B2 (en) 2010-05-06 2018-01-23 Aic Innovations Group, Inc. Apparatus and method for recognition of patient activities
SG191772A1 (en) 2011-01-31 2013-08-30 Cadila Healthcare Ltd Treatment for lipodystrophy
JP5919173B2 (ja) * 2012-11-22 2016-05-18 全星薬品工業株式会社 徐放性塩酸アンブロキソール口腔内崩壊錠
CN105120827B (zh) * 2013-03-14 2019-10-15 艾治疗技术公司 用于可疑活动辨别的装置和方法
AU2013387996B2 (en) 2013-04-22 2015-12-10 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (NAFLD)
US20160107989A1 (en) 2013-05-30 2016-04-21 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (es) * 2013-07-25 2015-06-26 Cadila Healthcare Ltd
IN2013MU02905A (es) 2013-09-06 2015-07-03 Cadila Healthcare Ltd
EP3137082A4 (en) * 2014-05-01 2018-02-28 Anterios, Inc. Methods to treat, prevent, and improve skin conditions
CN104127376B (zh) * 2014-08-04 2018-01-02 烟台荣昌制药股份有限公司 盐酸美金刚口服溶液
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
CN109922796B (zh) 2016-06-23 2023-04-07 考里安有限责任公司 具有亲水和疏水域的粘合剂基质和治疗剂
US10300025B2 (en) 2016-07-27 2019-05-28 Corium, Inc. Donepezil transdermal delivery system
AU2017301929B2 (en) * 2016-07-27 2023-03-02 Corium Pharma Solutions, Inc. Memantine transdermal delivery systems
WO2018055641A1 (en) * 2016-09-20 2018-03-29 Rubicon Research Private Limited Oral modified release formulations
TW201821068A (zh) * 2016-10-28 2018-06-16 美商查斯製藥公司 美金剛胺(memantine)組合及用途
BR112019011740A2 (pt) 2016-12-09 2019-10-29 Cadila Healthcare Ltd composição farmacêutica e método para o tratamento de colangite biliar primária
US20180235931A1 (en) * 2017-01-17 2018-08-23 Menlo Therapeutics Inc. Use of neurokinin-1 antagonists as antitussives
US11400054B2 (en) * 2017-06-30 2022-08-02 Industrial Technology Research Institute Method for treating an autoimmune neurological disease and/or neurodegenerative disease and pharmaceutical formulations for a liquid dosage form and a controlled release dosage form
US11170484B2 (en) * 2017-09-19 2021-11-09 Aic Innovations Group, Inc. Recognition of suspicious activities in medication administration
WO2019126531A1 (en) 2017-12-20 2019-06-27 Corium, Inc. Transdermal adhesive composition comprising a volatile liquid therapeutic agent having low melting point

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
MXPA05004422A (es) 2002-10-25 2007-11-22 Collegium Pharmaceutical Inc Composiciones de milnacipran de liberacion pulsatil.
US20040151771A1 (en) * 2003-02-04 2004-08-05 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
CN1240668C (zh) 2003-09-10 2006-02-08 上海医药工业研究院 一种新的盐酸美金刚制备方法
ES2483126T3 (es) 2004-06-17 2014-08-05 Merz Pharma Gmbh & Co. Kgaa Formulaciones de formas de dosificación de neramexano
US20060002999A1 (en) * 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
JP2008503475A (ja) 2004-06-17 2008-02-07 フォーレスト ラボラトリーズ， インコーポレイテッド メマンチンの放出が改変された製剤
WO2006053012A2 (en) 2004-11-10 2006-05-18 Trinity Laboratories, Inc. Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20090208579A1 (en) 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
SI1836157T1 (sl) 2005-01-11 2009-12-31 Teva Pharm Fine Chemicals Srl Postopek priprave 1-amino-3,5-dimetiladamantan hidroklorida
CA2604052C (en) 2005-04-06 2014-07-08 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of cns-related conditions
CN1709229A (zh) * 2005-06-10 2005-12-21 北京阜康仁生物制药科技有限公司 盐酸美金刚口腔崩解片及其制备方法
EA013474B1 (ru) 2005-06-16 2010-04-30 Форест Лэборэтериз, Инк. Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина
CN1742711A (zh) * 2005-09-23 2006-03-08 北京阜康仁生物制药科技有限公司 盐酸美金刚泡腾片及其制备方法
CA2675230A1 (en) 2006-01-10 2008-07-26 Pipex, Inc. Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
US20080014267A1 (en) * 2006-07-12 2008-01-17 Everett Laboratories, Inc. Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20070160689A1 (en) * 2006-01-12 2007-07-12 Everett Laboratories, Inc. Compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
KR101324898B1 (ko) 2006-03-31 2013-11-04 루비콘 리서치 피브이티. 엘티디. 구강 붕해 정제
IL175338A0 (en) 2006-05-01 2006-09-05 Biota Ltd Orally administrable films and preparation thereof
CA2650040A1 (en) 2006-05-02 2007-11-08 Panacea Biotec Ltd Transmucosal composition
WO2008001341A1 (en) 2006-06-27 2008-01-03 Biovail Laboratories International Srl Multiparticulate osmotic delivery system
WO2008005534A2 (en) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Orally dissolving formulations of memantine
EP2043613A1 (en) 2006-07-14 2009-04-08 Fmc Corporation Solid form
WO2008010794A1 (en) 2006-07-18 2008-01-24 Renaissance Medicine, Llc Pharmaceutical preparations of crystalline lazabemide
JP2010511595A (ja) 2006-07-31 2010-04-15 ニューロシステック コーポレイション 遊離塩基ガシクリジンナノ粒子
WO2008033155A1 (en) * 2006-09-15 2008-03-20 Auriga Laboratories, Inc. Kits for prevention and treatment of rhinitis
EP1902733A1 (en) 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
US20080078382A1 (en) 2006-09-20 2008-04-03 Lemahieu Edward Methods and Systems of Delivering Medication Via Inhalation
GB0623897D0 (en) 2006-11-30 2007-01-10 Pliva Istrazivanje I Razvoj D Pharmaceutical composition of memantine
EP2091939B1 (en) 2006-12-20 2011-03-16 Abbott Healthcare Products B.V. Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition
WO2008098195A2 (en) 2007-02-09 2008-08-14 Todd Maibach Film comprising nitroglycerin
WO2008116165A2 (en) 2007-03-21 2008-09-25 Next Safety, Inc. Methods and systems of delivering medication via inhalation
US20100239665A1 (en) 2007-05-01 2010-09-23 Ivan Coulter Pharmaceutical nimodipine compositions
WO2008140459A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
EP2155167A2 (en) * 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US20090004254A1 (en) 2007-06-19 2009-01-01 Todd Maibach Film comprising active drugs
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
WO2009002084A2 (en) 2007-06-27 2008-12-31 Hanmi Pharm. Co., Ltd. Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same
US8637080B2 (en) 2007-06-28 2014-01-28 Osmotica Kereskedelmi és Szolgáltató, KFT Rupturing controlled release device comprising a subcoat
US20100292341A1 (en) 2007-06-29 2010-11-18 Orchid Chemicals & Pharmaceuticals Limited Quick dissolve compositions of memantine hydrochloride
WO2009016486A2 (en) 2007-08-02 2009-02-05 Compugen, Ltd Use of nmda receptor antagonists for treatment of urologic tumors
US20100016262A1 (en) 2007-10-18 2010-01-21 Yale University Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis
EP2198857A1 (en) * 2008-12-19 2010-06-23 Ratiopharm GmbH Oral dispersible tablet

Also Published As

Publication number Publication date
US8501816B2 (en) 2013-08-06
US20140200271A1 (en) 2014-07-17
RU2013121270A (ru) 2014-11-20
EP2627323A1 (en) 2013-08-21
US20120121729A1 (en) 2012-05-17
CN103347506A (zh) 2013-10-09
CA2814194A1 (en) 2012-04-19
WO2012051333A1 (en) 2012-04-19
IL225716A0 (en) 2013-06-27
EP2627323A4 (en) 2014-03-12
AU2011316565A1 (en) 2013-05-02
BR112013008985A2 (pt) 2016-07-05
JP2013539790A (ja) 2013-10-28
SG189395A1 (en) 2013-05-31

Similar Documents

Publication Publication Date Title
MX2013004123A (es) Composiciones antitusigenas que comprenden memantina.
HK1216880A1 (zh) 某些***並吡啶化合物、其組合物和它們在治療癌症中的用途
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
AU328813S (en) Hand piece
CL2013000238A1 (es) Uso de inhibores de la succinato deshidrogenasa y/o inhibidores del complejo iii para mejorar la relacion entre microorganismos dañinos y beneficiosos.
AU323335S (en) Funnel
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
MY161601A (en) Films and compositions comprising the same
WO2009095261A3 (en) Vaccine compositions
WO2012073047A3 (en) Compositions and methods
AU332853S (en) Citrus press
MX343598B (es) Teobromina en combinacion con un expectorante o un mucolitico para uso en terapia.
IL214541A0 (en) Tricylic pyrazolopyrimidine derivatives, compositions comprising the same and uses thereof
MX344189B (es) Formulaciones de mazindol.
TR200909786A1 (tr) Sefiksim içeren efervesan tablet ve granül formülasyonu.
WO2012016026A3 (en) Electrolarynx devices and uses thereof
WO2010120400A3 (en) Substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carboxamides as tubulin polymerization inhibitors
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
TN2012000552A1 (en) An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
UA41660U (en) Use of jacton and mexidol as actoprotector
UA52378U (ru) Применение ЛИПОФЛАВОНА в качестве средства фригопротекторного действия
UA52376U (ru) Применение КОРВИТИНА в качестве средства фригопротекторного действия
UA52379U (ru) Применение ЛИПИНА в качестве средства фригопротекторного действия
UA61166U (en) Use of glucosamine hydrochloride as antiamnestic and antihypoxic agent

Legal Events

Date Code Title Description
FA Abandonment or withdrawal